CA2151240A1 - Administration de biophosphonate et d'oestrogene pour le traitement et la prevention de la perte osseuse - Google Patents

Administration de biophosphonate et d'oestrogene pour le traitement et la prevention de la perte osseuse

Info

Publication number
CA2151240A1
CA2151240A1 CA002151240A CA2151240A CA2151240A1 CA 2151240 A1 CA2151240 A1 CA 2151240A1 CA 002151240 A CA002151240 A CA 002151240A CA 2151240 A CA2151240 A CA 2151240A CA 2151240 A1 CA2151240 A1 CA 2151240A1
Authority
CA
Canada
Prior art keywords
estrogen
bisphosphonate
bone
bone loss
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002151240A
Other languages
English (en)
Inventor
Donna T. Whiteford
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2151240A1 publication Critical patent/CA2151240A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002151240A 1992-12-23 1993-12-17 Administration de biophosphonate et d'oestrogene pour le traitement et la prevention de la perte osseuse Abandoned CA2151240A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99641892A 1992-12-23 1992-12-23
US996,418 1992-12-23

Publications (1)

Publication Number Publication Date
CA2151240A1 true CA2151240A1 (fr) 1994-07-07

Family

ID=25542895

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002151240A Abandoned CA2151240A1 (fr) 1992-12-23 1993-12-17 Administration de biophosphonate et d'oestrogene pour le traitement et la prevention de la perte osseuse

Country Status (5)

Country Link
EP (1) EP0675723A4 (fr)
JP (1) JPH08505142A (fr)
AU (1) AU5953894A (fr)
CA (1) CA2151240A1 (fr)
WO (1) WO1994014455A1 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU687744B2 (en) * 1993-05-15 1998-03-05 Riemser Arzneimittel Ag More easily biologically absorbed tablet containing dichloromethylene diphosphonic acid as the active agent
US5646134A (en) * 1994-04-21 1997-07-08 Merck & Co., Inc. Alendronate therapy to prevent loosening of, or pain associated with, orthopedic implant devices
TW398975B (en) * 1994-07-22 2000-07-21 Lilly Co Eli Pharmaceutical composition for inhibiting bone loss
US5780455A (en) * 1994-08-24 1998-07-14 Merck & Co., Inc. Intravenous alendronate formulations
EP0824341A4 (fr) * 1995-05-12 1999-07-07 Merck & Co Inc Prevention des pertes de dnets par l'administration d'alendronate ou de ses sels
US5545635A (en) * 1995-05-23 1996-08-13 Eli Lilly And Company Inhibiting bone loss with equilenin
US5616571A (en) * 1995-06-06 1997-04-01 Merck & Co., Inc. Bisphosphonates prevent bone loss associated with immunosuppressive therapy
IL120270A0 (en) * 1996-02-28 1997-06-10 Pfizer Combination therapy to treat osteoporosis
IL120265A0 (en) * 1996-02-28 1997-06-10 Pfizer Combination therapy to treat osteoporosis - polyphosphonates or progestins and estrogen agonists
AU712710B2 (en) * 1996-05-17 1999-11-11 Merck Sharp & Dohme Corp. Effervescent bisphosphonate formulation
US5853759A (en) * 1996-05-17 1998-12-29 Merck & Co.. Inc. Effervescent alendronate formulation
EP1378234A1 (fr) * 1996-05-17 2004-01-07 MERCK & CO. INC. Formulation de bisphosphonate effervescente
WO1998023274A1 (fr) * 1996-11-25 1998-06-04 Merck & Co., Inc. Agents androgene et bisphosphonique coadministres pour traiter des maladies
US6376477B2 (en) 1996-11-25 2002-04-23 Merck & Co., Inc. Combination of an agent that binds to the androgen receptor and a bisphosphonic acid in the prevention and/or treatment of diseases involving calcium or phosphate metabolism
DE19719680A1 (de) 1997-05-09 1998-11-19 Boehringer Mannheim Gmbh Verwendung von Diphosphonsäuren zur präventiven Behandlung von Spätfolgen bei Harnblasenerweiterung oder Harnblasenersatz
CA2281937A1 (fr) * 1997-12-25 1999-07-08 Toray Industries, Inc. Medicament pour traiter les anormalites de moelle osseuse
DK1135140T3 (da) 1998-12-04 2005-12-19 Roche Diagnostics Gmbh Ibandronsyre til fremme af osseointegration af endoproteser
WO2000064516A1 (fr) * 1999-04-22 2000-11-02 Hydromed Sciences A Division Of Gp Strategies Corporation Administration regulee de bisphosphonates
AUPQ232599A0 (en) * 1999-08-19 1999-09-09 Royal Alexandra Hospital For Children, The Drug for treating fractures
FR2803521B1 (fr) * 2000-01-12 2002-10-25 Ceva Sante Animale Utilisation de l'acide tiludronique et de ses derives chez la volaille pour la preparation d'un medicament destine a prevenir et a traiter l'osteoporose
NZ527351A (en) 2001-02-06 2005-01-28 Royal Alexandra Hosp Children Use of bisphosphonate for the treatment of osteonecrosis and for the management of patients at risk of developing ostenonecrosis
WO2002080933A1 (fr) * 2001-04-03 2002-10-17 The Royal Alexandra Hospital For Children Medicament a utiliser en matiere de greffe osseuse
AUPR553701A0 (en) * 2001-06-07 2001-07-12 Royal Alexandra Hospital For Children, The A device for the delivery of a drug to a fractured bone
TWI315982B (en) 2001-07-19 2009-10-21 Novartis Ag Combinations comprising epothilones and pharmaceutical uses thereof
CA2470495A1 (fr) 2001-12-24 2003-07-17 Teva Pharmaceutical Industries Ltd. Forme posologique avec pastille noyau de principe actif enrobee dans un corps annulaire comprime de poudre ou de substance granulaire, et procede et outils pour la production de cette forme posologique
US7488496B2 (en) 2002-03-06 2009-02-10 Christer Rosen Effervescent compositions comprising bisphosphonates and methods related thereto
EP1508343B1 (fr) * 2003-08-21 2015-11-04 AddBIO AB Implant revêtu de bisphosphonate et son procédé de fabrication
JP5426168B2 (ja) * 2005-10-27 2014-02-26 トーメン メディカル アーゲー 歯科インプラント及びその製造方法
US8882740B2 (en) 2009-12-23 2014-11-11 Stryker Trauma Gmbh Method of delivering a biphosphonate and/or strontium ranelate below the surface of a bone

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3623397A1 (de) * 1986-07-11 1988-01-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
DE4029499A1 (de) * 1990-09-18 1992-03-19 Boehringer Mannheim Gmbh Neue 17-(beta)-oestradiolderivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
EP0496520A1 (fr) * 1991-01-22 1992-07-29 Merck & Co. Inc. Agents actifs sur les os
DK0573604T3 (da) * 1991-02-26 1995-05-29 Procter & Gamble Pharma Fremgangsmåde til behandling af osteoporosis

Also Published As

Publication number Publication date
WO1994014455A1 (fr) 1994-07-07
JPH08505142A (ja) 1996-06-04
AU5953894A (en) 1994-07-19
EP0675723A4 (fr) 1998-08-05
EP0675723A1 (fr) 1995-10-11

Similar Documents

Publication Publication Date Title
CA2151240A1 (fr) Administration de biophosphonate et d'oestrogene pour le traitement et la prevention de la perte osseuse
EP0756483B1 (fr) Emploi de biphosphonates inhibant la resorption osseuse consecutive a l'implantation d'une prothese orthopedique
EP0635270B1 (fr) Hormone parathyroide et raloxifène pour augmenter la masse d'os
JP2002529490A (ja) 歯牙吸収性病変の阻害方法
JP4989811B2 (ja) 副甲状腺ホルモンおよび骨吸収抑制剤を含む複合型薬学的製剤
US6399592B1 (en) Bishphosphonate/estrogen synergistic therapy for treating and preventing bone loss
JPH09328430A (ja) 骨粗鬆症治療のための組み合わせ療法
US6376477B2 (en) Combination of an agent that binds to the androgen receptor and a bisphosphonic acid in the prevention and/or treatment of diseases involving calcium or phosphate metabolism
JP2002526412A (ja) 跛行を処置するための医薬品製剤の製造におけるビスホスホン酸誘導体の使用
EA000677B1 (ru) Способ предотвращения остеопороза
CA2271664A1 (fr) Agents androgene et bisphosphonique coadministres pour traiter des maladies
AU2005203308A1 (en) Use of bisphosphonates for inhibiting bone resorption following implantation of orthopaedic prosthesis
AU9745901A (en) Use of bisphosphonates for inhibiting bone resorption following implantation of orthopaedic prosthesis
AU3574799A (en) Use of biphosphonates for inhibiting bone resorption following implantation of orthopedic prosthesis
MXPA96004968A (en) Use of bisphosphonates to inhibit bone rebassion after the implantation of orthopedic protesis
Forde Pharmacological Intervention in the Treatment of Osteoporosis: What's Old and What's New
MXPA97001526A (en) Combined therapy to treat osteoporo

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead